[COMPARATIVE STUDY OF THE HEART FUNCTIONAL RESERVE UNDER STRESS-INDUCED BLOCKADE OF NO-ERGIC SYSTEM AND GABA-A RECEPTORS IN RATS.].

Cardiac contractility in rats was decreased after 24-h immobilization-painful stressing, as indicated by lower growth rate of myocardium contraction and relaxation, LVP, heart rate, and maximum functioning intensity (MIF) in comparison to intact group during functional tests on adrenoreactivity and maximum isometric workload. Stressed animals pretreated with the GABA-A receptors blocker bicuculline (2 mg/kg, i.p.

[Cardioprotective effect of the new derivative of glutamic acid - glufimet in acute immobilization-painful stress in animals of different ages].

The effect of the 24-hour immobilization-painful stress on myocardial contractility of young (6-month), middle-aged (12-month) and old (24-month) female rats was studied. It was identified a reduction of the functional reserve of the heart, which showed a smaller growth rates of contraction and relaxation of the myocardium (+ dP/dt max and -dP/dt max), left ventricular pressure (LVP) and the maximum intensity of the functioning of the structures (MIFS) under increased pre- afterload and adrenergic stimulation of the heart, especially pronounced in the group of 24-month old rats. The animals of all ages treated before and after stressing glufimet in a dose 29 mg/kg, have higher rates of growth + dP/dt max, -dP/dt max, LVP and MIFS during load tests, most significant rates of growth are noticed in older rats compared with the young and middle-aged.

Effects of a New Glutamic Acid Derivative on Myocardial Contractility of Stressed Animals under Conditions of Nitric Oxide Synthesis Blockade.

Glufimet (glutamic acid derivative) in a dose of 28.7 mg/kg limited the reduction of the cardiac functional reserve in animals subjected to 24-h stress under conditions of nonselective NO synthase blockade with L-NAME (10 mg/kg). Adrenoreactivity and increased afterload tests showed that the increment of myocardial contraction/relaxation rates, left-ventricular pressure, and HR were significantly higher in glufimet-treated stressed animals with NO synthesis blockade than in animals which received no glufimet.

[NO-DEPENDENT MECHANISM OF THE CARDIOPROTECTIVE ACTION OF PHENIBUT ON STRESS-INDUCED VIOLATION OF CONTRACTILE FUNCTION OF THE HEART].

A stressor action for 24 h reduces both ino- and chronotropic reserves of animal heart as evidenced by a decrease in rate growth increments of contraction and relaxation of the myocardium, left ventricular pressure (LVP), heart rate, and the maximum intensity of functioning (MIF) as compared to intact animals during testing for adrenoreactivity and maximum isometric load caused by clamping of the ascending part of the aortic arch. Blockade of NO-synthase leads to a high percentage of animal death during the stressor action, anesthesia, opening of the chest, and functional tests and causes marked reduction in the growth rates of contraction (+dP/dt max) and relaxation (-dP/dt max) speed, LVP, heart rate, and MIF--on the average about 2 times (p < 0.05) under load testing conditions as compared to a control group of stressed animals.

[Cardioprotective properties of new glutamic acid derivative under stress conditions].

The effect of new glutamic acid derivative on the cardiac ino- and chronotropic functions has been studied in experiments on rats exposed to 24-hour immobilization-and-pain stress. It is established that glutamic acid derivative RGPU-238 (glufimet) at a dose of 28.7 mg/kg increases the increment of myocardial contractility and relaxation rates and left ventricular pressure in stress-tested animals by 13 1,1, 72.

[Change of cardiac ino- and chronotropic functions in stressed animals with blockade of different NO-synthases].

Aim: To investigate the effect of long-term immobilization-painful stress on ino- and chronotropic functions of the heart with inhibition of various NO-synthases.

Materials And Methods: 30 female albino rats were taken. Blockers of NO-system were: aminoguanidine (50 mg/kg), (50 mg/kg) and NG-nitro-L-arginine methyl ester (10 mg/kg).

[Evaluation of the efficiency of external assessment of the quality of determining antibodies to hepatitis C virus in the network of screening laboratories].

A regional external quality assessment (EQA) system for determining anti-hepatitis C virus (HCV) was developed and introduced. For this, a control panel comprising 14 samples with anti-HCV and 6 samples without anti-HCV was tested in the reference laboratory of Moscow Infectious Hospital One. A total of 6 sessions were conducted with the participation of 8 laboratories.

[Prevalence of HBV and HCV markers in patients of specialized medical institutions].

240 medical histories of patients admitted to Moscow clinical narcological hospital No. 17 with "opium addiction" diagnosis in 2000 and 2003 (120 histories for each year) were analyzed. From 1997 to 2003 4220 patients registered in narcological dispensary of Cherepovets city (Vologda region) were tested for HBsAg and anti-HCV.

[The spread of hepatitis B and C viruses and the structure of HBsAg subtypes in Kabardino-Balkaria].

A seroepidemiological study of the spread of hepatitis B and C viruses (HBV and HCV) was conducted among some population groups in Kabardino-Balkaria. The structure of HBsAg subtypes was also studied in the residents of the republic. The presence of viral hepatitis B markers among the test groups of the healthy population corresponds to the parameters of moderate activity of an epidemic process.

[Morbidity in acute virus hepatitis B on the territory of Kabardin-Balkaria].

Morbidity in acute virus hepatitis B (AVHB) in Kabardin-Balkaria during the period of 1992 to 2003 was analyzed. The dynamics of changes in the age groups of AVHB patients, as well as in the structure of the transmission routes of the disease, was analyzed. The level of AVHB morbidity in the Kabardin-Balkar Republic was lower in recent years than the average level of such morbidity in the whole of Russia.

[A comparative evaluation of detection of antibodies to hepatitis C virus in different immunoassay test system and verification tests].

Control tests and subsequent comparative analysis of their results related with the detection of anti-hepatitis C virus (anti-HCV) by different ELISA systems were made at a laboratory of the "Vector-Best" Company, Novosibirsk (A), a clinical diagnostic laboratory of Infection Clinical Hospital No. 1, No. 1 (B), and at a laboratory of chronic viral infections of Andjaparidze Institute of Viral Drugs of the Russian Academy of Medical Sciences (C).

[Viral hepatitis in different population groups of Republic of Sakha (Iakutia)].

A survey for the presence of markers of viral hepatitis B, delta, C and E among different groups of the population of the arctic and agricultural zones of the Republic of Sakha (Yakutia), as well as in Yakutsk, was carried out. The survey revealed that viral hepatitides with the parenteral mechanism of the transmission of infective agents were widely spread among the population. In the arctic zone HBsAg was detected in persons aged 20 years and older in 10.

[Evaluation of morbidity and etiological structure of acute and chronic viral hepatitis in the Sakha Republic (Yakutiia)].

The morbidity of viral hepatitis was epidemiologically analyzed and the etiological structure of severe and chronic viral hepatitis was studied in the Republic of Sakha (Yakutia). Acute viral hepatitis B, whose portion is 43.5%, was found to be of the key significance within the structure of acute viral hepatitis (AVH).

Limits of diagnostic accuracy of anti-hepatitis C virus antibodies detection by ELISA and immunoblot assay.

When human sera samples are tested for anti-hepatitis C virus (HCV) antibodies using different ELISA kits as well as immunoblot assay kits discrepant results often occur. As a result the diagnostics of HCV infection in such sera remains unclear. The purpose of this investigation is to define the limits of HCV serodiagnostics.

Performance of ELISA HBsAg Test Kits with Use of the Different Types of Panels Containing HBsAg.

Serological diagnostics of hepatitis B in clinical laboratories is mainly based on detection of HBs antigen (HBsAg) in human serum or plasma using commercial ELISA kits. In manufacturing and laboratory practice, sensitivity of ELISA kit is measured against either international or national reference standard. This approach is necessary, but limited as it does not take into account factors that influence on HBsAg detection kit potency at low HBsAg concentration and when HBsAg subtypes/variants are present in species.

[Evaluation of the system for controlling the quality of the HBsAg detection in the system of screening laboratories].

The two-stage control system, ensuring the high quality of serological investigations in the network of screening laboratories in Moscow was developed and introduced into practice. At the first stage the entry control of the quality of the test system for the detection of HbsAg, coming to the screening laboratories, is made in the reference laboratory with the use of specially developed "representative" panels, as well as the test systems for comparison ("reference" test systems). Then "minipanels" are formed from specimens included into the "representative" panels, which are used for the evaluation of the quality of laboratory investigations made in the screening laboratories.